checkAd

    Hier geht es heute rund - 500 Beiträge pro Seite

    eröffnet am 06.11.03 09:17:16 von
    neuester Beitrag 18.11.03 21:13:06 von
    Beiträge: 5
    ID: 793.245
    Aufrufe heute: 0
    Gesamt: 513
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 06.11.03 09:17:16
      Beitrag Nr. 1 ()
      TGOU in Amiland auf 2,45$
      Hier für 2€ und jetzt die News.

      Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory

      Wednesday, November 05, 2003 09:01 ET

      IRVINE, Calif., Nov 5, 2003 (BUSINESS WIRE) -- Too Gourmet, Inc. (OTCBB:TGOU) is pleased to announce that it has completed the acquisition of the medical business assets and related intellectual property of a medical laboratory and service provider, doing business as the Internationale Fachklinik (" lab" ) located in Schwerin, Germany from Prof. Dr. Hans-Jurgen Reimann and Dr. Antje Reimann.

      In connection with the acquisitions, Prof. Reimann will be appointed to serve as the company`s Chairman of the Board and as its Chief Executive Officer. Dr. A. Reimann will be appointed to the Board of Directors of the company. The international law firm of Bryan Cave LLP will continue its engagement with the company as its corporate securities counsel.

      Under the direction of Prof. Reimann, Professor at University of Rostock and at Humboldt University in Berlin, Germany, PhD. in Biochemistry and PhD. in Medicine, the lab specializes in the research, analysis, and in vitro diagnosis of live biopsy tissue samples for allergic, immunological, and environmentally related disorders. In order to improve the quality of test results, Prof. Reimann developed and patented a unique device known as a " Tabox" , which enables the precise analysis of the effects of allergens and toxins on the human body in an in vitro environment.

      Currently, the lab operates a total of twenty-eight inter-clinic Tabox systems as proprietary devices, which are available to practitioners, clinics, and other medical clients on a lease-only basis. The lab charges its lessees a user fee for each tissue sample processed at the lab. According to Prof. Reimann, the operation of twenty-eight Tabox systems at capacity could generate revenues of up to $2.8 million annually. Prof. Reimann anticipates the production and use of up to one hundred Tabox systems by its clients by the end of the third quarter of 2004. During the 2003 calendar year, the lab has reported revenues of approximately $1.2 million and pre-tax profits of approximately 30% of sales.

      The company is in preliminary negotiations to acquire all of the outstanding stock of a German medical devices, equipment, and apparatus manufacturer that currently produces the Tabox for the lab. " The purchase of the equipment manufacturer could be a strategic acquisition, ensuring timely production and commercial " roll out" of the proprietary Tabox systems and expansion of the lab`s services in Western Europe," said Prof. Reimann. " In addition, the manufacturer`s fiscal performance could contribute significantly to the company`s revenues and earnings in 2004. Furthermore, the acquisition of the manufacturer could help to diversify the company`s products and services portfolio into other potentially profitable niche markets." The manufacturer anticipates revenues of approximately $7.5 million and pre-tax profits of approximately $2.0 million in the current calendar year 2003.

      The Private Securities Litigation Reform Act of 1995 provides a " safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements related to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of Too Gourmet, Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, and domestic and global economic conditions.

      SOURCE: Too Gourmet, Inc.



      :eek: :eek:
      Avatar
      schrieb am 06.11.03 09:25:18
      Beitrag Nr. 2 ()
      675548 :cool:
      Avatar
      schrieb am 06.11.03 09:57:36
      Beitrag Nr. 3 ()
      661768:cool:
      So jetzt wacht der Makler in Berlin auch so langsam auf.:D
      Avatar
      schrieb am 06.11.03 10:15:52
      Beitrag Nr. 4 ()
      Hat mal jemand das Orderbuch Berlin,geht bei mir gerade nicht.
      Danke
      MP:cool:
      Avatar
      schrieb am 18.11.03 21:13:06
      Beitrag Nr. 5 ()
      steigt und steigt :eek: :eek:

      52W HIGH: New 52-Wk High for TGOU @ $2.940 up3.52%

      Tuesday , November 18, 2003 12:36 ET

      This is the 3rd 52 WEEK HIGH alert for TGOU in the past 7 calendar days.

      The share price for Too Gourmet Incorporated (OTCBB: TGOU) reached a new 52-week high today, trading at $2.940, up $0.100 (3.52%) from its previous close of $2.840.

      The Company`s previous 52-week high of $2.850 was set yesterday on November 17, 2003.

      One year ago, the Company`s shares closed at $1.250. The price has climbed more than 135 percent since then.

      At the time of this alert, the stock had traded 3,500 shares via 3 trades, 82.62% below it`s 20day average of 20,139 shares.

      This new 52-week high currently puts the stock:

      62.03% above its 20day Moving Average of $1.815
      235.08% above its 50day Moving Average of $0.877
      408.65% above its 100day Moving Average of $0.578

      The Company last released news on November 05, 2003:

      "Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory"


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Hier geht es heute rund